info@tajpharma.com +91 84484 44095 / 8071 555 357
Vapi, Gujarat, India WHO-GMP Certified

Clinical Information for Healthcare Providers

Comprehensive prescribing guidelines and clinical data for Dolutegravir-based HIV treatment

Prescribing Guidelines
Dosing Information
Drug Interactions
Patient Monitoring

Prescribing Guidelines

Patient Selection

Dolutegravir is suitable for:

  • Treatment-naive adults and adolescents
  • Treatment-experienced patients
  • Pregnant women (with counseling)
  • Children weighing ≥6 kg
  • Patients with renal impairment
Baseline Assessment

Before initiating Dolutegravir, conduct:

  • HIV-1 RNA viral load testing
  • CD4+ cell count
  • Resistance testing (if available)
  • Hepatitis B and C screening
  • Pregnancy test (women of childbearing age)
  • Renal function assessment

Dosing Information

Adult and Adolescent Dosing
Population Dose Frequency Notes
Adults & adolescents ≥12 years, ≥40 kg 50 mg Once daily Standard dosing
With rifampin 50 mg Twice daily Increased due to enzyme induction
With certain anticonvulsants 50 mg Twice daily May require dose adjustment
Renal impairment 50 mg Once daily No dose adjustment needed
Mild hepatic impairment 50 mg Once daily No dose adjustment
Pediatric Dosing (TAPIVIR DT 10)
Weight Range Daily Dose Tablets per Day
6 to <10 kg 15 mg 1.5 tablets
10 to <14 kg 20 mg 2 tablets
14 to <20 kg 25 mg 2.5 tablets
20 to <30 kg 30 mg 3 tablets
≥30 kg 40 mg 4 tablets

Drug Interactions

Medications That Reduce Dolutegravir Absorption

Action: Take Dolutegravir 2 hours before or 6 hours after these medications

  • Antacids (aluminum, magnesium, calcium)
  • Calcium supplements
  • Iron supplements
  • Multivitamins containing polyvalent cations
Acid-Reducing Agents
  • H2 receptor antagonists: Take Dolutegravir 12 hours before or 4 hours after
  • Proton pump inhibitors: May reduce Dolutegravir levels; monitor viral load
Enzyme Inducers
  • Rifampin: Increase Dolutegravir to 50 mg twice daily
  • Carbamazepine: May require Dolutegravir dose adjustment
  • Phenytoin: May require Dolutegravir dose adjustment
  • Phenobarbital: May require Dolutegravir dose adjustment
  • St. John's Wort: AVOID - significantly reduces Dolutegravir levels
Other Important Interactions
  • Metformin: Dolutegravir increases metformin levels; may need dose adjustment
  • Other antiretrovirals: Generally compatible; check specific combinations

Patient Monitoring and Follow-up

Viral Load Monitoring
  • Week 4: First viral load check (should show decline)
  • Week 12: Second viral load check (should be undetectable)
  • Every 3-6 months: Ongoing monitoring after suppression
  • Goal: <50 copies/mL (undetectable)
CD4+ Count Monitoring
  • Baseline: Before starting treatment
  • Every 3-6 months: During treatment
  • Goal: CD4 count >200 cells/mm³ (prevents most OIs)
  • Note: May take months to years to fully recover
Clinical Assessment
  • Adherence: Assess at each visit; provide support
  • Side effects: Manage or switch regimen if needed
  • Opportunistic infections: Screen based on CD4 count
  • Comorbidities: Monitor for cardiovascular, renal, bone health
  • Mental health: Screen for depression and provide support

Special Populations

Pregnancy

WHO recommends Dolutegravir for pregnant women with appropriate counseling. Benefits generally outweigh risks. Continue throughout pregnancy and postpartum.

Pediatric Patients

Use weight-based dosing with dispersible tablets. Excellent efficacy and tolerability. Monitor growth and development regularly.

Renal Impairment

No dose adjustment needed for any degree of renal impairment. Safe in patients with eGFR <15 mL/min.

Hepatic Impairment

Use with caution in severe hepatic impairment. No dose adjustment needed for mild to moderate impairment.

Managing Side Effects

Insomnia

Take Dolutegravir in the morning. Recommend good sleep hygiene. Avoid caffeine late in the day. Usually improves within 2-4 weeks.

Nausea/Diarrhea

Take with food. Recommend small, frequent meals. Stay hydrated. Usually resolves within first few weeks.

Headache

Usually mild and transient. Over-the-counter analgesics may help. Typically resolves within days to weeks.

Mood Changes

Screen for depression at baseline and during treatment. Refer to mental health services if needed. Consider alternative regimen if severe.

Managing Treatment Failure

Detectable Viral Load After 12 Weeks

If viral load remains detectable after 12 weeks of treatment:

  1. Assess adherence - most common cause
  2. Perform resistance testing
  3. Consider drug interactions
  4. Evaluate for malabsorption
  5. Modify regimen based on resistance results

Need Clinical Support?

Call Our Team

+91 84484 44095

24/7 Toll-Free Helpline

Email Us

info@tajpharma.com

For detailed clinical information